Supplementary Fig. S1



Supplementary Fig. S1. Assessment of cell viability of CDDP treated hOMK and hOMF in the range of 0.01 – 100 µg/mL.
5 and 10 µg/mL CDDP for 48 hours treated hOMKand hOMF showed significant reduction of cell viability in WST assay ($p < 0.01$).

Supplementary Fig. S2



Supplementary Fig. S2. Changes in the morphology of hOMK and hOMF after the treatment with CDDP.
Cell morphology of hOMK and hOMF in each group. Magnification ×200.

Target	Supplier	Catalog number
Human β-actin	Thermo Fisher Science	Hs01060665_g1
Human IL-6	Thermo Fisher Science	Hs00174131_m1
Human IL-8	Thermo Fisher Science	Hs00174103_m1
Human MMP-2	Thermo Fisher Science	Hs01548727_m1
Human MMP-9	Thermo Fisher Science	Hs00957562_m1

Supplementary Table S1: Prime probe list used for Real-time RT-PCR in this study